• Home
  • Latest
  • Fortune 500
  • Finance
  • Tech
  • Leadership
  • Lifestyle
  • Rankings
  • Multimedia

Trendingnow

1

AI CEOs from OpenAI, Anthropic, and Microsoft set aside their rivalry to warn Congress AI is making it too easy to design and create bioweapons

2

MacKenzie Scott's approach to her $26 billion giving spree was inspired by a book she read in college about writing

3

Social Security faces a 24% cut in 2032—that's a $345 billion hit to retirees nationwide, watchdog says

1

AI CEOs from OpenAI, Anthropic, and Microsoft set aside their rivalry to warn Congress AI is making it too easy to design and create bioweapons

2

MacKenzie Scott's approach to her $26 billion giving spree was inspired by a book she read in college about writing

3

Social Security faces a 24% cut in 2032—that's a $345 billion hit to retirees nationwide, watchdog says
HealthCoronavirus

You may have COVID rebound even without taking Paxlovid. Here are the three symptoms most likely to return, according to one study

By
Alexa Mikhail
Alexa Mikhail
Senior Reporter, Fortune Well
Down Arrow Button Icon
By
Alexa Mikhail
Alexa Mikhail
Senior Reporter, Fortune Well
Down Arrow Button Icon
November 17, 2022, 1:40 PM ET
For people who don't take Paxlovid, the body's immune response can still make rebound infection possible.
For people who don't take Paxlovid, the body's immune response can still make rebound infection possible.WESTEND61—GETTY IMAGES

Paxlovid, the antiviral drug used to treat COVID, isn’t the only reason you could be experiencing rebound symptoms, a new study suggests. In the study, published in JAMA Network last month, over a third of those infected with COVID who didn’t take Paxlovid still experienced a recurrence of their symptoms two days after their initial recovery. 

The study, conducted between August and November of 2020, looked at over 150 people who did not take Paxlovid (they were given a placebo) after contracting the virus. After about a month, 68% recovered fully, and of that group, 44% reported they had recurring symptoms of at least one of 13 common COVID symptoms after two days of reporting zero symptoms (like chills, cough, fatigue, headache, muscle or body pain, nausea and sore throat).  

The overwhelming majority (85%) of people with recurring symptoms said they were mild, and most commonly reported cough, fatigue, or a headache. Fifteen percent of those with recurring symptoms reported at least one moderate symptom. 

“Reported symptoms are inherently subjective, and our observed variation may explain some of the rebound of symptoms after treatment for COVID-19, like in cases of what has been described as Paxlovid rebound,” the authors write. 

People have feared taking Paxlovid, the antiviral treatment for COVID, because of the reported rebound effect, where people’s symptoms come back after they recover from the illness. 

Researchers are still working to understand the rebound infection phenomenon, but many explain it as people’s immune systems not being able to fully fight off the virus yet. 

“Your immune system hasn’t really had a chance to catch up and really create enough antibodies to have a sustained response,” Dr. Andrew Jameson, section chief of infectious diseases at Trinity Health Saint Mary’s Hospital, previously told Fortune. 

Still, experts have touted Paxlovid’s ability to curb the risk of getting severely sick or dying from the virus—its main purpose. People who are eligible, those who are older or at risk for developing severe illness from COVID, are recommended to take the antiviral within five days of contracting the virus. 

And for people who don’t take Paxlovid, the body’s immune response can still make rebound infection possible—everyone responds to the virus differently, and that includes recovering briefly and getting sicker a couple days later. Older people are more at risk for these rebound infections, Dr. Preeti Malani, an infectious diseases physician at The University of Michigan, tells Fortune. 

“Recovery is not a straight line,” she says. “It just has to do with how your immune system takes care of the virus,” so expect symptoms to potentially increase and decrease after initial infection. 

The study was conducted prior to the rollout of COVID vaccines, as well as the emergence of new variants like Omicron that have manifested differently across communities. Therefore, the results don’t take into account people’s current immunity from vaccination nor their response to different variants. While the thought of recovering only to get sick again is more than frustrating, experts underscore that there are things that can prevent severe illness. Those vaccinated are at much less risk for severe disease, hospitalization, and death.

About the Author
By Alexa MikhailSenior Reporter, Fortune Well
LinkedIn iconTwitter icon

Alexa Mikhail is a former senior health and wellness reporter for Fortune Well, covering longevity, aging, caregiving, workplace wellness, and mental health.

See full bioRight Arrow Button Icon

Latest in Health

Finance
Lorem ipsum dolor sit amet, consectetur adipiscing elit, sed do eiusmod tempor incididunt ut labore et dolore magna aliqua. Ut enim ad minim veniam
By Fortune Editors
October 20, 2025
Finance
Lorem ipsum dolor sit amet, consectetur adipiscing elit, sed do eiusmod tempor incididunt ut labore et dolore magna aliqua. Ut enim ad minim veniam
By Fortune Editors
October 20, 2025
Finance
Lorem ipsum dolor sit amet, consectetur adipiscing elit, sed do eiusmod tempor incididunt ut labore et dolore magna aliqua. Ut enim ad minim veniam
By Fortune Editors
October 20, 2025
Finance
Lorem ipsum dolor sit amet, consectetur adipiscing elit, sed do eiusmod tempor incididunt ut labore et dolore magna aliqua. Ut enim ad minim veniam
By Fortune Editors
October 20, 2025
Finance
Lorem ipsum dolor sit amet, consectetur adipiscing elit, sed do eiusmod tempor incididunt ut labore et dolore magna aliqua. Ut enim ad minim veniam
By Fortune Editors
October 20, 2025
Finance
Lorem ipsum dolor sit amet, consectetur adipiscing elit, sed do eiusmod tempor incididunt ut labore et dolore magna aliqua. Ut enim ad minim veniam
By Fortune Editors
October 20, 2025

Most Popular

Finance
Lorem ipsum dolor sit amet, consectetur adipiscing elit, sed do eiusmod tempor incididunt ut labore et dolore magna aliqua. Ut enim ad minim veniam
By Fortune Editors
October 20, 2025
Finance
Lorem ipsum dolor sit amet, consectetur adipiscing elit, sed do eiusmod tempor incididunt ut labore et dolore magna aliqua. Ut enim ad minim veniam
By Fortune Editors
October 20, 2025
Finance
Lorem ipsum dolor sit amet, consectetur adipiscing elit, sed do eiusmod tempor incididunt ut labore et dolore magna aliqua. Ut enim ad minim veniam
By Fortune Editors
October 20, 2025
Finance
Lorem ipsum dolor sit amet, consectetur adipiscing elit, sed do eiusmod tempor incididunt ut labore et dolore magna aliqua. Ut enim ad minim veniam
By Fortune Editors
October 20, 2025
Finance
Lorem ipsum dolor sit amet, consectetur adipiscing elit, sed do eiusmod tempor incididunt ut labore et dolore magna aliqua. Ut enim ad minim veniam
By Fortune Editors
October 20, 2025
Finance
Lorem ipsum dolor sit amet, consectetur adipiscing elit, sed do eiusmod tempor incididunt ut labore et dolore magna aliqua. Ut enim ad minim veniam
By Fortune Editors
October 20, 2025
Fortune Secondary Logo
Rankings
  • 100 Best Companies
  • Fortune 500
  • Global 500
  • Fortune 500 Europe
  • Most Powerful Women
  • World's Most Admired Companies
  • See All Rankings
  • Lists Calendar
Sections
  • Finance
  • Fortune Crypto
  • Features
  • Leadership
  • Health
  • Commentary
  • Success
  • Retail
  • Mpw
  • Tech
  • Lifestyle
  • CEO Initiative
  • Asia
  • Politics
  • Conferences
  • Europe
  • Newsletters
  • Personal Finance
  • Environment
  • Magazine
  • Education
Customer Support
  • Frequently Asked Questions
  • Customer Service Portal
  • Privacy Policy
  • Terms Of Use
  • Single Issues For Purchase
  • International Print
Commercial Services
  • Advertising
  • Fortune Brand Studio
  • Fortune Analytics
  • Fortune Conferences
  • Business Development
  • Group Subscriptions
About Us
  • About Us
  • Press Center
  • Work At Fortune
  • Terms And Conditions
  • Site Map
  • About Us
  • Press Center
  • Work At Fortune
  • Terms And Conditions
  • Site Map
  • Facebook icon
  • Twitter icon
  • LinkedIn icon
  • Instagram icon
  • Pinterest icon

© 2026 Fortune Media IP Limited. All Rights Reserved. Use of this site constitutes acceptance of our Terms of Use and Privacy Policy | CA Notice at Collection and Privacy Notice | Do Not Sell/Share My Personal Information
FORTUNE is a trademark of Fortune Media IP Limited, registered in the U.S. and other countries. FORTUNE may receive compensation for some links to products and services on this website. Offers may be subject to change without notice.


Latest in Health

As the World Cup draws millions to 11 U.S. cities, measles—not Ebola—may be the biggest concern
HealthHealth
As the World Cup draws millions to 11 U.S. cities, measles—not Ebola—may be the biggest concern
By Marco Quiroz-GutierrezJune 5, 2026
15 hours ago
Melinda French Gates is done waiting for health care to take menopause seriously
MPWMost Powerful Women
Melinda French Gates is done waiting for health care to take menopause seriously
By Emma HinchliffeJune 5, 2026
19 hours ago
Cronometer Review (2026): Calorie Tracking and More
HealthDietary Supplements
Cronometer Review (2026): Calorie Tracking and More
By Emily PharesJune 5, 2026
20 hours ago
Nitrosurge Pre-Workout Review (2026): Expert Tested
HealthDietary Supplements
Nitrosurge Pre-Workout Review (2026): Expert Tested
By Christina SnyderJune 5, 2026
20 hours ago
AI CEOs from OpenAI, Anthropic, and Microsoft set aside their rivalry to warn Congress AI is making it too easy to design and create bioweapons
AITech
AI CEOs from OpenAI, Anthropic, and Microsoft set aside their rivalry to warn Congress AI is making it too easy to design and create bioweapons
By Marco Quiroz-GutierrezJune 5, 2026
1 day ago
The label from a box of peptides next to 10 vials of an orange substance.
CryptoCryptocurrency
I bought peptides with crypto. How my purchase helped fuel a $100 million gray-market, ‘looksmaxxing’ economy
By Ben WeissJune 4, 2026
2 days ago

Most Popular

AI CEOs from OpenAI, Anthropic, and Microsoft set aside their rivalry to warn Congress AI is making it too easy to design and create bioweapons
AI
AI CEOs from OpenAI, Anthropic, and Microsoft set aside their rivalry to warn Congress AI is making it too easy to design and create bioweapons
By Marco Quiroz-GutierrezJune 5, 2026
1 day ago
MacKenzie Scott's approach to her $26 billion giving spree was inspired by a book she read in college about writing
Success
MacKenzie Scott's approach to her $26 billion giving spree was inspired by a book she read in college about writing
By Sydney LakeJune 5, 2026
1 day ago
Social Security faces a 24% cut in 2032—that's a $345 billion hit to retirees nationwide, watchdog says
Economy
Social Security faces a 24% cut in 2032—that's a $345 billion hit to retirees nationwide, watchdog says
By Nick LichtenbergJune 5, 2026
1 day ago
Current price of oil as of June 5, 2026
Personal Finance
Current price of oil as of June 5, 2026
By Joseph HostetlerJune 5, 2026
22 hours ago
Ohio city workers are covering automated license plate readers with trash bags as officials sound the alarm on 'egregious violations' of privacy
Cybersecurity
Ohio city workers are covering automated license plate readers with trash bags as officials sound the alarm on 'egregious violations' of privacy
By Sasha RogelbergJune 3, 2026
3 days ago
'Big Tech is desperate': Amazon engineers are calling out the tech giant for its $200 billion in data center spending after slashing 30,000 workers
Environment
'Big Tech is desperate': Amazon engineers are calling out the tech giant for its $200 billion in data center spending after slashing 30,000 workers
By Sasha RogelbergJune 5, 2026
1 day ago